The fecal pancreatic elastase testing market is expected to increase from USD 15,306.7 million in 2023 to USD 31,842.3 million by 2033. The market is likely to capture a 7.6% CAGR from 2023 to 2033.
Pancreatic cancer is a leading cause of cancer-related death among young women. With a very poor overall diagnosis and prognosis that has remained constant for many years. As a result, the global pancreatic cancer market offers numerous prospects to improve therapy and diagnosis.
The emergence of new drug regimens and new drug combinations extends the survival of 80% of patients. Obesity and a lack of physical activity are linked to pancreatic cancer. Some nutritional and dietary factors are the causes of an increasing population suffering from pancreatic cancer disease. Such as a high fat intake, a low vegetable intake, and red and processed meat consumption. These are dominating the global market due to new technological advances in surgical therapies, chemotherapies, and radiation therapies. Increasing the managerial abilities of healthcare personnel to aid in surgery, chemotherapy, and radiotherapy to save people's lives.
Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic cancers. Pancreatic cancer risk factors include familial risk due to susceptibility gene mutations, chronic pancreatitis, pancreatic cysts, and diabetes mellitus. Risk factors include smoking, alcohol misuse, obesity or metabolic syndrome, aging, and occupational exposure. Around 80% of patients with pancreatic cancer have advanced disease or distant metastases, and there are no feasible therapeutic options.
Even those who are suitable for early resection have a 5-year survival rate of 31%. Next-generation genome sequencing (NGS) advances have sparked renewed interest in the topic. By facilitating the identification of molecular alterations that drive pancreatic cancer growth.
| Report Attribute | Details |
|---|---|
| Fecal Pancreatic Elastase Testing Market Value (2023) | USD 15,306.7 million |
| Fecal Pancreatic Elastase Testing Market Anticipated Value (2033) | USD 31,842.3 million |
| Fecal Pancreatic Elastase Testing Market Growth Rate (2023 to 2033) | 7.6% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The fecal pancreatic elastase testing market accounted for USD 11,712.13 million in 2018 to USD 14,399.56 million in 2022, expanding at a 5.3% CAGR from 2017 to 2022.
The increased prevalence of exocrine pancreatic insufficiency caused by chronic pancreatitis is driving the demand for fecal pancreatic elastase testing. In addition, sedentary lifestyles and increased drunkenness drive the market. Resulting in decreased elastase production and pancreatic damage.
According to several studies, the prevalence of exocrine pancreatic insufficiency is rising due to an increase in cystic fibrosis cases worldwide. Exocrine pancreatic insufficiency affects around 85% of cystic fibrosis patients.
For early treatment, fecal pancreatic elastase tests can detect this EPI. As the frequency of cystic fibrosis rises, so does the demand for fecal pancreatic elastase testing.
Every year, around 70,000 people worldwide are impacted by cystic fibrosis, according to the Cystic Fibrosis Foundation. As a result, early diagnosis, and therapy for clients, as well as fecal pancreatic elastase testing, are critical.
Chronic pancreatitis (CP) is diagnosed by observing changes in the structure or function of the diseased pancreas. Pancreatic function tests are more sensitive than structural testing in diagnosing chronic pancreatitis, especially in the early stages of the disease.
Non-invasive and invasive function testing are the two sorts of tests. Invasive tube tests can reliably detect moderate to early CP. They are only available at a few referral hospitals and are frequently unpopular with patients.
Non-invasive diagnostics are widely available; they function poorly in patients with early, mild diseases. As a result, improvement, and development in the fecal pancreatic elastase testing sector, such as simple, non-invasive, cost-effective, and accurate pancreatic function tests, aid market expansion.
| Historical CAGR (2018 to 2022) | 5.3% |
|---|---|
| Forecast CAGR (2023 to 2033) | 7.6% |
As per the FMI analysts, a valuation of USD 31,842.3 million by 2033 end is estimated for the market.
An enzyme created by the pancreas is called pancreatic elastase. As part of the digestion process, this enzyme breaks down lipids, proteins, carbs, and so on. Changes in pancreatic elastase levels determine if the pancreas is working properly or not. A decrease in its level implies pancreatic insufficiency.
The primary drivers in this market are rising levels of obesity in persons as a result of sedentary lifestyles and increased drunkenness. Moreover, greater competitiveness among individuals can further lead to extreme stress levels.
Diabetes mellitus patients saw a significant decrease in the amount of pancreatic elastase. This research has the potential to be utilized to diagnose diabetes in suspected persons by early testing, allowing for better disease treatment.
Pancreatic insufficiency can be caused by a variety of pancreatic disorders, including chronic and acute pancreatitis. Pancreatitis accounts for around 86,000 hospital admissions in the United States each year. This emphasizes the importance of experimenting with novel ways of its management.
A study published in the Wiley Online Library regarding the diagnostic strategy. To determine whether a more therapeutic strategy can be used to treat pancreatic insufficiency after pancreatitis. According to their findings, early diagnosis has numerous advantages in this case. Since it minimizes future issues in nutrition malabsorption and leads to adequate and prompt treatment. This can be accomplished through regular and timely testing of pancreatic elastase.
They concluded by saying that adequate dietary changes not only prevent issues related to the malabsorption of these nutrients but also maintain nutritional status at normal levels.
The diagnosis of exocrine pancreatic insufficiency includes a critical step called stool analysis. The presence of steatorrhea is determined by the 72-hour fecal fat test. Traditionally, the patient must consume 8 to 12 grams of fat per day on a regular diet for five days before the last 72-hour stool sample can be taken.
This testing is time-consuming for the patient and not widely accepted because 100 grams of fat must be taken daily. Additionally, measuring fecal fat is an imprecise indicator of fat malabsorption. It is only appropriate in cases when more than 90% of pancreatic function has been lost.
This test is currently considered to be outmoded and has been replaced by more readily available techniques including breathalyzer testing and fecal elastase measurements. Throughout the forecast period, this is anticipated to offer market participants growth prospects.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
With the low exocrine pancreatic insufficiency knowledge among the general public, the demand for fecal pancreatic elastase testing is constrained.
EPI symptoms include constipation, diarrhea, stomach pain, bloating, greasy stools, and unexplained weight loss. These symptoms can also be produced by a wide range of other illnesses. As a result, it is possible to misread the symptoms and receive an incorrect diagnosis. Furthermore, people frequently ignore these small symptoms.
The average time it took those with ongoing GI problems to see a doctor was 3.7 years, according to the American Gastroenterological Association. Furthermore, according to 60% of respondents, it is embarrassing to discuss GI problems with a doctor.
Nearly 47% said they just wanted to wait and see if their problems go away. Exocrine pancreatic insufficiency (EPI) was only known to 21% of patients who were interviewed, and 66% had never heard of it.
So, a lack of knowledge could restrict the market's expansion for fecal pancreatic elastase testing.
| Countries | CAGR Value (2023 to 2033) |
|---|---|
| United States | 28.6% |
| Germany | 10.1% |
| Japan | 0.8% |
| Australia | 3.40% |
| China | 7.30% |
| India | 6.20% |
| United Kingdom | 9.00% |
With a total market share of almost 28.6% from 2023 to 2033, the United States held the top spot in North America. It is anticipated that this trend continues throughout the projection period.
The increase in pancreatitis and pancreatic insufficiency diseases is ascribed to the increased drinking culture. Alcohol consumption, which affects more than 85% of persons over the age of 18, can lead to several critical health issues. Including a possibly deadly and agonizing pancreatic inflammation.
During the anticipated period, Germany is anticipated to develop at a CAGR of about 10.1% in the European market. Due to the presence of leading market competitors, ongoing development, and an increase in research and inventions, market growth is anticipated to expand.
For instance, German innovators at ScheBo Biotech AG produced a test kit in 2021. It includes a pancreatic elastase 1-specific antibody and a tool for sample collection. Compared to the current kits, it is substantially more accurate at detecting elastase levels in feces.
China accounted for fecal pancreatic elastase testing in East Asia in 2022. Its share is expected to capture a CAGR of 7.30% throughout the forecast period. This expansion is linked to an increase in demand for pancreatic elastase tests.
Exocrine pancreatic insufficiency has been identified using a preliminary diagnostic technique called a fecal fat test. Fecal pancreatic elastase testing is becoming more popular among end users due to several drawbacks and cumbersome processes.
India accounted for 33.3% of the market for fecal pancreatic elastase testing in East Asia in 2021. It is anticipated that over the forecast period, it thrives at a CAGR of 6.20%. The prevalence of pancreatic-related problems, such as chronic pancreatitis, is on the rise, which supports this expansion.
In the country between 2022 and 2032, there be a lucrative opportunity due to the rise in diseases and difficulties and the rate of diagnostic and testing alternatives.
The market for fecal pancreatic elastase ELISA kits is anticipated to expand profitably. According to FMI, the market share for the segment was above 99.7% in 2022. Because it offers a very sensitive and precise way to measure fecal pancreatic elastase.
It helps the medical professional to diagnose suspected pancreatic insufficiency patients quickly and accurately. High accuracy, sensitivity, and specificity boost demand in the market over the forecasted period.
In 2022, chronic pancreatitis held a 34.6% revenue share. With the prevalence of chronic pancreatitis rising globally, it is anticipated to have the market share.
It is critical to do early testing and identification to prevent further health issues. EPI in adults is primarily brought on by chronic pancreatitis. Eight out of ten adults with chronic pancreatitis experience exocrine pancreatic insufficiency.
With a market share of more than 37.1% in 2022, hospitals held the top spot in the market. This is because these tests can be conducted in hospitals by highly qualified medical personnel. Additionally, specialized equipment is utilized to run the test.
Manufacturers use several essential techniques to expand their customer base. Including new product releases, technological advancements, partnerships, and distribution agreements between market participants.
Recent Development:
| Attribute | Details |
|---|---|
| Market Size Value in 2023 | USD 15,306.7 million |
| Market Size Value at End of Forecast (2033) | USD 31,842.3 million |
| Market Analysis | USD million for Value |
| Key Region Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; The Middle East and Africa |
| Key Segments | By Product, By Indication, By End User, By Region |
| Key Companies Profiled | Laboratory Corporation of America® Holdings; DiaSorin; ScheBo Biotech AG; Immundiagnostik AG; Invivo Healthcare; DRG Instruments GMBH; Verisana Laboratories; BÜHLMANN Laboratories AG; CerTest Biotec S.L.; R-Biopharm AG; American Laboratory Products Company, Ltd.; Vitassay Healthcare, S.L.U. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Fecal pancreatic elastase testing globally is forecasted to surge at 7.6% CAGR until 2033.
The net worth of such services available worldwide in 2023 could be nearly USD 15,306.7 million.
The overall market developed at a moderate 5.3% CAGR from 2017 to 2022.
The United States contributed for almost 28.6% of the global market share in 2023.
Germany is the leading market in Europe with a global market share of 10.1%
| Estimated Size, 2024 | USD 60.4 billion |
|---|---|
| Projected Size, 2034 | USD 136.7 billion |
| Value-based CAGR (2024 to 2034) | 8.5% |
Explore In-vitro Diagnostics Devices Insights
View Reports
Fecal Pancreatic Elastase Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
